Cite
HARVARD Citation
Weisel, K. et al. (2022). Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia & lymphoma. 63 (8), pp. 1887-1896. [Online].